GLP-1s

R&D

In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.

R&D

Sandeep Kulkarni, CEO of Tourmaline Bio, discusses inflammation, & the impact of AI and GLP-1s on cardiology clinical trials and drug development.

R&D

Global pharmaceutical market projections through 2030, with Norstella's Daniel Chancellor.

R&D

At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.

R&D

In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.

News

Novo Nordisk will cut 9,000 jobs across the company as it reallocates resources toward growth and innovation in the obesity and diabetes markets.